Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Illumina, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Illumina, Inc.

Regulatory records
2
Linked recall entries
6
Headquarters
Not reported
Brand website
illumina.com
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Illumina, Inc.. It includes 1 original PMA approval. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 21, 2024 to Sep 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PQP appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P230011, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 5200 Illumina Way, San Diego, CA, 92122. Recorded on P230011/S008, decision dated Sep 4, 2026.

Changes described in PMA records

P230011/S008: TruSight Oncology Comprehensive

FDA posted a decision dated 2026-09-04 for supplement S008 to PMA P230011, TruSight Oncology Comprehensive from Illumina, Inc. The decision code is OK30, and the supplement type is a 30-Day Notice. The stated reason is a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes a supplier manufacturing site change.

This notice does not represent a new approval of the whole system or a new indication. The database fields do not state which supplier, which manufacturing site, or what specific manufacturing activity changed. The device is categorized as a next generation sequencing oncology panel, somatic or germline variant detection system under product code PQP and pathology specialty.

FDA approval-order wording

a supplier manufacturing site change

Sep 4, 2026 · 30-Day Notice

P230011: TruSight Oncology Comprehensive

The FDA approved Illumina's TruSight Oncology Comprehensive as a qualitative in vitro diagnostic using targeted next-generation sequencing on the Illumina NextSeq 550Dx instrument. It detects variants across 517 genes from DNA extracted from formalin-fixed, paraffin-embedded tumor tissue of patients with solid malignant neoplasms, including single nucleotide variants, multi-nucleotide variants, insertions, and deletions. RNA analysis covers fusions in 24 genes and splice variants in one gene, and the test reports a Tumor Mutational Burden score.

The approval statement describes two intended uses: as a companion diagnostic for targeted therapies listed in Table 1 of the statement, and for tumor profiling information used by qualified health care professionals according to oncology guidelines. Genomic findings beyond Table 1 are not conclusive or prescriptive for labeled use of any specific therapeutic product. The database record does not include a supplement type or reason, so no changed item or original PMA relationship is established.

FDA approval-order wording

TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multi- nucleotide variants, insertions, and deletions from DNA, and fusions in 24 genes and splice variants in one gene from RNA. The test also reports a Tumor Mutational Burden (TMB) score.The test is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the targeted therapies listed in Table 1, in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 of the intended use statement are not conclusive or prescriptive for labeled use of any specific therapeutic product.

Aug 21, 2024

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 6 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 6 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 19, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Illumina, Inc.PMA supplementSep 4, 2026FDA
Illumina, Inc.PMA approvalAug 21, 2024FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.